BMO downgrades Replimune stock on FDA rejection concerns - Stock Watch Index

BMO downgrades Replimune stock on FDA rejection concerns

April 13, 2026

BMO downgrades Replimune stock on FDA rejection concerns

Search

RECENT PRESS RELEASES

Wheels of Change: Automation in India’s Automotive Sector

SWI Editorial Staff2026-04-13T04:47:40-07:00April 13, 2026|

Chinese EV exports jump 124% amid energy crunch

SWI Editorial Staff2026-04-13T04:47:40-07:00April 13, 2026|

Ineos Automotive: Startup backed by a knighted billionaire and soccer mogul wants to rekin

SWI Editorial Staff2026-04-13T04:30:01-07:00April 13, 2026|

As Data Centers Test Michigan’s Grid, It’s Time to Strengthen Clean Energy Standards—Not Abandon Them

SWI Editorial Staff2026-04-13T04:30:00-07:00April 13, 2026|

‘Can’t make a squeak’: Trump’s fossil fuel push puts IMF, World Bank on defensive

SWI Editorial Staff2026-04-13T04:30:00-07:00April 13, 2026|

Tesla is selling 250 invite-only Model S ‘Signatures’ for $160,000

SWI Editorial Staff2026-04-13T04:15:55-07:00April 13, 2026|

Related Post